Asset sale vs stock sale for a licensed practice

Most owners meet this question for the first time inside a letter of intent, several weeks into a process, with far less leverage than they had at the start.

It is worth deciding before you go to market, because for a licensed behavioral health practice the answer is often not actually open — and knowing that early is leverage rather than a disclosure.

The two structures

An asset sale. The buyer purchases the things the business owns and uses — equipment, client relationships, goodwill, and whichever contracts can be assigned. Your legal entity stays with you, along with its history, and you wind it down afterwards.

A stock sale (or membership-interest sale, if you are an LLC). The buyer purchases the entity itself. Everything the entity holds comes along automatically, because nothing changes hands except ownership of the company. Its contracts, its licences, its liabilities and its history all continue uninterrupted.

The difference sounds technical. It determines what your buyer actually receives and what you are still responsible for afterwards.

Why buyers ask for an asset sale first

Two reasons, and both are legitimate rather than sharp practice.

Basis step-up. In an asset sale the buyer generally gets to reset the tax basis of what they bought to what they paid, which produces deductions over the following years. That is worth real money to them, and it is the main reason an asset sale is the default ask.

Liability. Buying assets means leaving most of the entity’s history behind — old claims, prior payer exposure, employment matters. Buying the entity means buying its past along with its present.

Expect the first draft of any letter of intent to propose an asset sale. It is not an attempt to disadvantage you; it is what their advisers recommend by default.

Why licensure often forces the other answer

Here is the argument this page exists to make.

Authorisations are issued to entities, and entities do not change in an asset sale — they get left behind.

A state certificate of approval, CCBHC status, a CMHC designation, an opioid treatment programme licence, accreditation from CARF or the Joint Commission: these attach to the legal entity that applied for them. If the buyer purchases your assets, they have not purchased your authorisations, because those were never assets. They belong to a company you still own and are about to dissolve.

Which means the buyer has to apply in their own name. That takes months, and in some categories considerably longer, with a survey or site visit in the middle. Until it completes, the programme those authorisations permit cannot bill — sometimes cannot operate.

So a practice whose value rests on hard-won authorisations is often only sellable as an entity. The structure is not really a negotiating position; it is a consequence of what you hold. See what buyers look for for how those authorisations are valued in the first place.

Payer contracts behave the same way

The same logic, applied to the thing that actually generates your revenue.

Group payer contracts are held by the entity. In an asset sale they terminate, and the buyer must contract and credential afresh — every payer, every clinician.

That gap has a cost. Sessions still happen. Clinicians still get paid. Claims either cannot be submitted or are submitted and denied. Depending on the payer mix, the gap runs from a couple of months to well past half a year, and it lands entirely in the period right after closing when the buyer has just spent their money.

Buyers know this and price it — as a lower number, a larger holdback, or an earnout contingent on revenue actually surviving the transition. If your contracts are group-held and transferable, that is worth arguing for explicitly, because it removes a risk they would otherwise charge you for.

What actually transfers, item by item

Abstractions are hard to argue with. Specifics are not. Here is the same practice under both structures.

In a stock sale, these come along automatically, because the entity that holds them is what changed hands: state authorisations and accreditation, group payer contracts and the group NPI, the employer identification number, clinician employment agreements and their restrictive covenants, the lease, the phone number and fax line the referral sources have, the malpractice history, and every liability the entity has ever incurred.

In an asset sale, each of those has to be dealt with individually, and they divide into three groups:

• Assignable with consent. The lease, most vendor contracts, sometimes an equipment loan. Each consent is somebody’s signature you now need, and each is a small piece of leverage handed to a third party mid-deal.
• Not assignable at all. State authorisations, accreditation, the group NPI. The buyer applies afresh, in their own name, on their own timeline.
• Left behind entirely. The entity, its history, its liabilities — which is precisely what the buyer wanted, and part of why they asked.

Employment agreements deserve a specific mention. In an asset sale your clinicians are not transferred; they are terminated and rehired by the buyer. Every restrictive covenant you carefully put in place is extinguished at that moment, and whether a new one exists depends on what each clinician agrees to sign for their new employer. That is a real risk to the asset, it happens at the most unsettled moment in the practice’s life, and it is one of the strongest arguments a seller has for structuring the deal the other way.

What changes for you

Tax treatment differs between the two structures, and sometimes substantially. An asset sale generally allocates the price across different categories of asset which are taxed differently, and if you hold the practice in a corporation there may be a layer of tax at the entity level before anything reaches you. A stock sale is usually simpler for the seller.

That is as far as this page will go, deliberately. The actual answer depends on your entity type, your basis, your state, and how long you have held it — and getting it wrong is expensive in a way that reading about it generally cannot fix. Talk to your CPA before you go to market, not after you have signed a letter of intent. The structure is much harder to change once it is in writing.

Your risk after closing also differs. In a stock sale the buyer inherits the entity’s history, so they will want protection: representations and warranties, an escrow holdback of part of the price, and a survival period during which claims can be made against it. Expect a meaningful share of the price to be held back for a year or more. That is normal, and the amount and duration are negotiable — at the letter of intent stage, and effectively nowhere else.

Deciding before you go to market

If your authorisations and payer contracts make an entity sale the only workable structure, say so in the first substantive conversation.

Sellers often hold this back, worried it reads as a constraint that weakens them. It does the opposite. It tells a serious buyer that you understand what they are actually acquiring, it removes weeks of negotiation over a structure that was never viable, and it filters out buyers who were only ever going to work on their preferred terms.

Discovering it in week six of exclusivity, when your alternatives have gone away, is the version that costs you.

---

Nothing on this page is legal, tax or accounting advice, and it cannot be — the answer depends on facts about your practice that a guide cannot know. It is here so that the conversation with your attorney and your CPA starts from a better place.

If you are earlier than this, the valuation calculator is free and takes about four minutes.